This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Alere's CEO Discusses Q4 2011 Results - Earnings Call Transcript

Additionally, please note that during this call, we may discuss non-GAAP financial measures. For each non-GAAP financial measure discussed, a presentation of the most directly comparable GAAP financial measure and a reconciliation of the differences between the non-GAAP financial measure discussed and the most directly comparable GAAP financial measure is available on the company's website at

And with that, let me turn the call over to Alere Chairman and CEO, Ron Zwanziger. Ron?

Ron Zwanziger

Thanks, Doug, and good morning, everyone. Our fourth quarter results were impacted by significant headwinds, which emerged in Europe and went through the quarter and not only affected our financial results but our comfort in setting and operating to our 2012 earnings outlook. On the positive side, sales growth in Asia Pacific region was strong, global new product sales showed encouraging acceleration, and our Health Management unit continued to stabilize. Finally, in the fourth quarter, we reentered the diabetes marketplace and began to address the primary missing element in our portfolio approach towards the most expensive chronic diseases. I'll expand briefly now on some of these elements.

While Europe remained relatively strong during the first 10 months of the year, our November, December were particularly weak. While we had been highlighting the risk in Europe on earnings call during the past year, the abruptness which the situation deteriorate was still frankly surprising to us. While we're pleased that sales in Europe have been steady so far in the first quarter, continued uncertainty over the macroeconomic environment combined with how quickly ordering patterns can change has us feeling uncomfortable about predicting the European outlook for 2012. This concern compounded by an ease over the potential for further declines in U.S. states spending on health improvements programs led us in an Investor Conference in January to provide only minimal guidance around 2012 earnings. At that conference, we said that we expect to exceed $250 million in adjusted cash basis EPS in 2012, but the extent to which we exceed that minimum target cannot be predicted at this time, which continues to be our view today.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community


Chart of I:DJI
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 +1.21 0.06%
NASDAQ 4,828.3250 +15.6170 0.32%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs